| 48.43 BATS BZX Real-Time Price As of 3:07pm ET |  +0.71 / +1.49%Today’s Change | 41.23 Today|||52-Week Range 52.83 | +5.12% Year-to-Date |
| Gilead-Galapagos Ink $5.1B Deal for Additional Compounds Jul 15 / Zacks.com - Paid Partner Content | Novo to Broaden Exposure to Pilbara Gold-Bearing Lag Gravels Via Letter of Intent Wit... Jun 28 / GlobeNewswirePNW - Paid Partner Content |
| Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY Jul 12 / Zacks.com - Paid Partner Content | Novo to Present at the John Tumazos Very Independent Research Metals and Natural Reso... Jun 18 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 47.72 |
| Today’s open | 48.40 |
| Day’s range | 48.16 - 48.45 |
| Volume | 1,436,699 |
| Average volume (3 months) | 1,362,205 |
| Market cap | $85.9B |
| Earnings growth (last year) | +8.07% |
| Earnings growth (this year) | +0.72% |
| Earnings growth (next 5 years) | +8.90% |
| Revenue growth (last year) | +4.51% |
| P/E ratio | 20.3 |
| Price/Sales | 6.31 |
| Price/Book | 14.33 |
| Today’s change | Today’s % change | |
|---|---|---|
| BMYBristol-Myers Squibb | -0.25 | -0.56% |
| ABBVAbbVie | -0.31 | -0.45% |
| GSKGlaxoSmithKline | -0.03 | -0.07% |
| SNYSanofi | -0.15 | -0.36% |
| Next reporting date | August 9, 2019 |
| EPS forecast (this quarter) | $0.61 |
| Annual revenue (last year) | $17.7B |
| Annual profit (last year) | $6.1B |
| Net profit margin | 34.54% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President & Chief Executive Officer Lars Fruergaard Jørgensen |
Executive Vice President- International Operations Maziar Mike Doustdar |
Corporate headquarters Bagsværd, Capital Region |
